key: cord-0756025-5i726g2m
authors: Bonnet, Udo; Juckel, Georg
title: COVID-19 Outcomes: Does the Use of Psychotropic Drugs Make a Difference? Accumulating Evidence of a Beneficial Effect of Antidepressants—A Scoping Review
date: 2022-04-14
journal: J Clin Psychopharmacol
DOI: 10.1097/jcp.0000000000001543
sha: e761128448bef28be50e6115283e039ad8dcbde9
doc_id: 756025
cord_uid: 5i726g2m

PURPOSE/BACKGROUND: Studies for repurposed drugs in severe acute respiratory syndrome coronavirus type 2–infected and coronavirus disease 2019 (COVID-19) patients are ongoing. According to preclinical research, antidepressants (ADs) might be useful in the treatment of COVID-19. METHODS/PROCEDURES: We conducted a scoping review including clinical studies on AD effects on SARS-CoV-2 infection and COVID-19. FINDING/RESULTS: As of January 2, 2022, we found 14 clinical studies, which could be included into this review. Among them, there were 2 randomized, placebo-controlled studies and 2 prospective parallel-group studies about the efficacy/effectiveness and tolerability of fluvoxamine. The remaining studies were mainly retrospective studies considering COVID-19 hospital populations predominantly exposed to fluoxetine (N = 3), other selective serotonin reuptake inhibitors (SSRI), selective norepinephrine reuptake inhibitors (SNRI), and trazodone. The vast majority were hospital studies and assessed COVID-19 severity (morbidity) and mortality as primary endpoints. The only outpatient study (fluvoxamine) investigated the COVID-19–related hospitalization rate, and 1 psychiatric hospital study (SSRI, SNRI, trazodone) focused on the SARS-CoV-2 infection rate. IMPLICATIONS/CONCLUSIONS: At present, the best evidence of an “anti–COVID-19” potential of ADs exists for fluvoxamine and, to a lesser extent, for fluoxetine. Preliminary evidence had found that patients exposed to SSRI or SNRI substance classes might have a reduced mortality risk and that trazodone might reduce SARS-CoV-2 infection rates. Three studies found no relevant influence of ADs on COVID-19 morbidity and mortality, and 1 study described increased mortality. The latter study, however, did not differentiate between psychotropic medication and ADs. Tricyclics and monoamine oxidase inhibitors are still absolute “dark zones” in COVID-19 research. Further controlled studies testing the effectiveness/efficacy and tolerability/safety (as well as the treatment timing and duration) of different AD substance classes in COVID-19 and post/long-COVID patients of various populations are warranted.

P eople with severe mental illness (eg, schizophrenia spectrum disorder, bipolar disorder, unipolar depression) have been repeatedly shown to be at increased risk to experience a severe coronavirus disease 2019 course and to die in relation therewith. [1] [2] [3] [4] Per recent findings, however, this risk might be not driven by the psychiatric condition itself. Instead, it appears that the somatic comorbidity burden might play the dominant role in the development of COVID-19 morbidity and mortality, also in this special population of psychiatric patients. 5, 6 However, what do we know about the contribution of the concomitant psychopharmacotherapy? Do psychotropic medications also impact the COVID-19 outcome significantly? This question is especially interesting because COVID-19 severity is based at least partly on an excessive immune response on the severe acute respiratory syndrome coronavirus type 2 infection and a lot of psychoactive drugs possess the power necessary to modulate and might have an impact on such immune reactions. [7] [8] [9] A Danish cross-sectional administrative database study 1 and an Italian meta-analysis of Vai et al 4 have checked a potential influence of psychotropic drugs on COVID-19 severity of psychiatric patients. The Danish large database study found that redemption of psychotropic drugs (lithium, antipsychotics, antidepressants [ADs], psychostimulants) was significantly associated with a poorer COVID-19 outcome (evidence-based medicine [EBM] level 3, Table 1 ). 1 Vai et al 4 reported that COVID-19 mortality was significantly associated with prescriptions of antipsychotics and anxiolytics, whereas ADs had no relevant impact on surviving after adjusting for confounding variables (EBM level 2, Table 1 ). Although evaluating large samples, in both studies, the association of COVID-19 prognosis with psychotropic medications 1,4 could have been profoundly biased by the current psychiatric and somatic condition as well as the related lifestyle behavior on health. The same would apply to the results of a smaller Spanish observational study, which, on the contrary, demonstrated a beneficial influence of some ADs on COVID-19-related mortality of psychiatric inpatients. 10 To conclude, harmful or even protective effects of psychotropic drugs could have been largely confounded by the psychiatric indication and the overall psychosocial burden independent on COVID-19.

Just taking a closer look on ADs, it appears that increasing more-in-depth investigations 7, 9, 10 point to a predominantly useful effect of these drugs against SARS-CoV-2 infections and the development of severe COVID-19 cases. This encouraged us to conduct the following scoping review 11 including clinical studies on this possibly promising drug repurposing approach for COVID-19.

A scoping systematic review 11 was performed using the search term combinations "antidepressants" and "study" and "COVID" OR SARS-COV" in https://pubmed.ncbi.nlm.nih.gov/ up to January 2, 2022. Furthermore, we evaluated the secondary literature of the resulting 117 or 49 hits with respect to our inclusion criteria: case reports, or clinical or epidemiological studies about the influence of ADs on COVID-19 outcomes or on patients' infection (n = 3401 exposed to SSRI vs n = 80,183 not exposed to SSRI, cp) In comparison with matched cp, the RR of mortality was reduced among patients prescribed any SSRI (14.6% vs cp 16.6%, adj P = 0.03); prescribed fluoxetine (9.8% vs cp 13.3%, adj P = 0.03); prescribed fluoxetine or fluvoxamine (10% vs cp 13.3%, adj P = 0.03%); prescribed SSRI that is not fluoxetine or fluvoxamine ( 

We could include 14 studies (Fig. 1) , which were summarized in Table 1 . In short, 2 placebo-controlled randomized studies, 12, 13 both EBM level 2, demonstrated a beneficial role of fluvoxamine (100 mg twice a day or 3 times a day over 14 days) as add-on in the treatment of COVID-19: in these studies, 12,13 fluvoxamine significantly reduced serious COVID-19 outcomes. This and the good tolerability and safety of fluvoxamine were supported by a small pragmatic prospective Croatian study (EBM level 3). 14 Another small pragmatic prospective study tested a fluvoxamine loading dose protocol (50 to 100 mg, followed by 50 mg twice a day) alongside 14 days in SARS-CoV-2-positive adult outpatients, who were not necessarily affected by COVID-19. In this 14-day study, fluvoxamine treatment predicted fewer hospitalizations and residual symptoms of SARS-CoV-2-infected patients (EBM level 3). 15 The second best evidence of an "anti-COVID" potential of ADs exists for fluoxetine; at present, it is shown only in retrospective studies: 1 larger study (EBM level 3) 16 and the other 2 with smaller sample sizes (EBM level 3 17 ; EBM level 4). 18 The smallest study in this context (EBM level 4) 18 tested an add-on treatment of 20 mg fluoxetine up to 28 days in patients receiving an antiviral treatment of COVID-19 pneumonia, whereas the other 2 studies 16,17 had dose uncertainties. Other selective serotonin reuptake inhibitors (SSRI), mirtazapine, venlafaxine, and trazodone were associated with reduced SARS-CoV-2 infection rates as well as reduced COVID-19 morbidity and mortality in 4 retrospective studies, 1 with psychiatric inpatients (EBM level 3) 17 and the other 3 evaluating larger general hospital samples affected by COVID-19, all EBM level 3. 7, 9, 19 Three further retrospective studies described no relevant influence of ADs on COVID-19 severity and mortality, 2 of them using small sample sizes (EBM level 3 20 and EBM level 4), 21 and the remaining study with a large heterogeneous COVID-19 population (EBM level 2). 4 The least specific study was cross-sectional and described that psychotropic drugs (including ADs) were associated with increased COVID-19 severity and mortality in the Danish general population (EBM level 3). 1

At present, especially fluvoxamine (100 mg twice a day or 3 times a day) seems to exert protective effects on COVID-19 morbidity and mortality (supported by 2 randomized placebocontrolled clinical trials [both EBM level 2, Table 1 ] 12,13 and 1 pragmatic prospective study [EBM level 3, Table 1 ]). 14 The only outpatient study included into this review used lower fluvoxamine doses (50 mg twice a day) in an outpatient everyday setting and found significantly reduced COVID-19-related hospitalization (EBM level 3, Table 1 ). 15 In this context, it should be outlined that fluvoxamine, like other ADs, is no "panacea," given its special pharmacokinetics as a powerful inhibitor of the CYP11A2 and CYP2C19 systems as well as an average inhibitor of CYP3A4, all together catabolic pathways with a relevant genetic variability in the general population. 22 Against this background, problematic drug-drug interactions have been reported with fluvoxamine, such as considerable increases of the blood levels of, for example, diazepam, bromazepam, alprazolam, clozapine, tricyclics, mirtazapine, and many other somatic medications as well as adverse effects during cross-over titration from fluvoxamine (itself mainly metabolized by CYP2D6 and CYP1A2) to other serotonergic drugs. 22, 23 Citing the last Cochrane analysis, fluvoxamine was neither superior nor inferior to any other ADs in terms of efficacy and tolerability in the acute phase treatment of depression; 24 especially nausea/vomiting was more frequently reported with fluvoxamine than with tricyclics. 24 According to the studies elaborated here, fluvoxamine was well tolerated by COVID-19 patients (Table 1 ). More data are necessary about dosing, treatment timing and duration, tolerability/safety in various populations, and effectiveness/efficacy against post/long COVID and different SARS-CoV-2 variants. We read that 4 larger trials are underway in United States and Canada. 25 

The idea to test the anti-COVID-19 potential of fluvoxamine, an old and inexpensive SSRI, however less frequently prescribed in these days, was based upon preclinical research, where fluvoxamine was shown to augment a cellular key anti-inflammatory system by stimulating the sigma-1 receptor (SIR-1), an endoplasmic reticulum (ER) chaperone membrane protein involved, for example, in the control of the ER stress response. 12 For instance, SIR-1 was identified as an essential inhibitor of cytokine production in a murine model of septic shock . 26 Another SSRI, that is, fluoxetine, was demonstrated to inhibit SARS-CoV-2 entry into epithelial cells as well as SARS-CoV-2 replication. [27] [28] [29] [30] Because fluoxetine and fluvoxamine share a potent SIR-1 agonism, it is possible that both SSRIs can prevent severe COVID-19 by abating hyperinflammatory events, such as the cytokine storm after ER stress due to SARS-CoV-2 replication. 27, 31 Moreover, decreased immunoglobulin E-mediated mastcell degranulation and interference with endolysosomal viral trafficking were discussed as mechanisms to limit this hyperinflammatory immune response. 31, 32 A recent large retrospective clinical register study corroborated that both fluoxetine and fluvoxamine prescriptions negatively predicted COVID-19 mortality (EBM level 3, Table 1 ). 16 Moreover, an anti-COVID-19 potential of fluoxetine was supported by 2 further, although smaller, retrospective studies. 17, 18 Further Broader Possible Anti-COVID-19

The SIR-1 agonist effect as a central explanation of the effect of fluvoxamine remains to date uncertain in the absence of any preclinical or clinical data specific to COVID-19 supporting this effect and seems unable to explain associations observed between non-SIR-1 or very-low SIR-1 ADs (such as paroxetine, mirtazapine, and venlafaxine) and reduced risk of intubation or death (Table 1) 19 as well as anti-inflammatory effects observed with a broad range of ADs (and not only the SIR-1 ADs fluvoxamine and fluoxetine) in individuals with major depression. 8 Contrariwise, several preclinical (in vitro and ex vivo) and observational studies suggest that inhibition of acid sphingomyelinase (ASM)/ceramide system plays a potentially important role and may explain both potential antiviral and anti-inflammatory effects of certain ADs in COVID-19. 32, 33 Particularly, among SSRIs, the magnitude of the in vitro inhibition of ASM, which varies across molecules (eg, fluoxetine > paroxetine > fluvoxamine > other SSRIs), 34, 35 appears to correlate with the magnitude of the in vitro antiviral effect against SARS-CoV-2. 28, 36 In this context, most ADs belong to a large group of special lipophilic, lysosomotropic, amine, and weak bases (comprising also many tricyclic ADs, some antipsychotics like chlorpromazine and promethazine, and nonpsychotropic drugs, such as organic calcium antagonists and ambroxol), which can inhibit the lysosomal and cell-surface ASM. [33] [34] [35] [36] [37] [38] This enzyme converts sphingomyelin to phosphorylcholine and ceramide, and high ceramide concentrations in the cell membrane are assumed to weaken the membrane integrity, thereby possibly supporting virus entry. 2 Three studies found that plasma ceramide levels strongly correlate with clinical and inflammation severity among patients with COVID-19. [39] [40] [41] Intriguingly, SARS-CoV-2 infection was demonstrated to stimulate even this ASM/ceramide system. 2 Thus, an inhibition of sphingomyelin break down by the aforementioned special weakly basic drugs, socalled functional inhibitors of acid sphingomyelinase (FIASMAs), might by a promising approach to prevent SARS-CoV-2 entry into cells. 19, 27, [33] [34] [35] [36] [37] [38] Indeed, the latter phenomenon was demonstrated with tricyclics (amitriptyline, imipramine, maprotiline) as well as SSRI (sertraline, fluoxetine, escitalopram); all of which prevented infection of nasal epithelial cells with SARS-CoV-2. 27 Furthermore, volunteers treated with a low dose of amitriptyline developed no infection of freshly isolated nasal epithelial cells with pseudoviral particles presenting SARS-CoV-2 spike protein, a model preferentially used for mimicking SARS-CoV-2 infection. 27 In addition, the non-SSRI trazodone was found to be associated with a protective effect on SARS-CoV-2 infection rates. 17 In this context, a German retrospective clinical study pointed also to protective influences of the whole substance class of ADs on respiratory COVID-outcomes; however, the statistical significance of this effect faded after adjustment to multiple testing (EBM level 3, Table 1 ). 20 Remarkably, this study had a preferential use of venlafaxine, duloxetine, mirtazapine, agomelatine, sertraline, and citalopram but, in fact, had examined zero cases with fluoxetine and fluvoxamine treatment (unreported information). 20 Nevertheless, it cannot be excluded that the accidental absence of fluoxetine and fluvoxamine treatments had negatively modulated the results of this explorative clinical study. 20 Beyond SIR-1 and FIASMA potential mechanisms, the antiplatelet activity of SSRIs might be beneficial to COVID-19 prognosis. 9, 19, 36 Finally, it is still possible that the whole substance class of ADs can be characterized by an intrinsic property of filtering overactive destructive immune responses by reducing proinflammatory cytokine activities and increasing anti-inflammatory cytokine activities, 8, 20 thereby curbing also a consecutive post-COVID autoimmunity. Toward this end, beyond or overlapping with their FIASMA activity, ADs might control destructive immune activity by increasing the resilience of vulnerable cells, in general, for example, by activating non-SIR-1-inositol-requiring enzyme pathways, 32, 36 balancing a disturbed tryptophan metabolism, 42, 43 limiting oxidative stress, promoting mild intracellular acidification (assumed to be cyto/neuroprotective), 44, 45 and/or increasing the net vagal influence. 46 

At present, the best evidence of an anti-COVID-19 potential of ADs exists for fluvoxamine and, to a lesser extent, for fluoxetine. Preliminary evidence was found for other SSRI, selective norepinephrine reuptake inhibitors, and trazodone exposures. Tricyclics and MAO inhibitors are still "dark zones" in COVID-19 research. Further wellcontrolled studies testing the effectiveness/efficacy and tolerability/ safety (and treatment timing/duration) of different AD substance classes in COVID-19 patients of various populations are warranted.

Severe mental illness is associated with increased mortality and severe course of COVID-19

Longer-term mortality following SARS-CoV-2 infection in people with severe mental illness: retrospective case-matched study

A meta-analysis: the mortality and severity of COVID-19 among patients with mental disorders

Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: a systematic review and meta-analysis

Comorbid medical conditions are a key factor to understand the relationship between psychiatric disorders and COVID-19-related mortality: results from 49,089 COVID-19 inpatients

Is a diagnosis of schizophrenia spectrum disorder associated with increased mortality in patients with COVID-19?

Addictive drugs and their relationship with infectious diseases

Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis

Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study

Mental disorders, psychopharmacological treatments, and mortality in 2150 COVID-19 Spanish inpatients

Guidance for conducting systematic scoping reviews

Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial

Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial

Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls

Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19. Open forum

Mortality risk among patients with COVID-19 prescribed selective serotonin reuptake inhibitor antidepressants

Analysis of the impact of antidepressants and other medications on COVID-19 infection risk in a chronic psychiatric in-patient cohort

Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: a retrospective case-control study

Association between FIASMAs and reduced risk of intubation or death in individuals hospitalized for severe COVID-19: an observational multicenter study

Impact of psychiatric and related somatic medications on the duration and severity of COVID-19: a retrospective explorative multi-center study from the German metropolitan Ruhr-area

Can SSRI/SNRI antidepressants decrease the 'cytokine storm' in the course of COVID-19 pneumonia? Panminerva Med

Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence

A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder

Fluvoxamine versus other anti-depressive agents for depression

Fluvoxamine for the early treatment of SARS-CoV-2 infection: a review of current evidence

Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis

Pharmacological inhibition of acid sphingomyelinase prevents uptake of SARS-CoV-2 by epithelial cells

Targeting the endolysosomal host-SARS-CoV-2 interface by clinically licensed functional inhibitors of acid sphingomyelinase (FIASMA) including the antidepressant fluoxetine

Combination therapy with fluoxetine and the nucleoside analog GS-441524 exerts synergistic antiviral effects against different SARS-CoV-2 variants in vitro

The serotonin reuptake inhibitor fluoxetine inhibits SARS-CoV-2 in human lung tissue

Old drug fluvoxamine, new hope for COVID-19

Repurposing antidepressants inhibiting the sphingomyelinase acid/ceramide system against COVID-19: current evidence and potential mechanisms

Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells

Functional inhibitors of acid sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications

The acid sphingomyelinase/ceramide system in COVID-19

Do the selective serotonin reuptake inhibitor antidepressants fluoxetine and fluvoxamine reduce mortality among patients with COVID-19?

Repurposing functional inhibitors of acid sphingomyelinase (FIASMAs): an opportunity against SARS-CoV-2 infection

Identification of novel functional inhibitors of acid sphingomyelinase

Inferring a causal relationship between ceramide levels and COVID-19 respiratory distress

Severity of COVID-19 patients predicted by serum sphingolipids signature

Metabolic signatures associated with severity in hospitalized COVID-19 patients

Increased kynurenine-to-tryptophan ratio in the serum of patients infected with SARS-CoV2: an observational cohort study

COVID-19, interferons, and depression: a commentary

Modulatory effects of neuropsychopharmaca on intracellular pH of hippocampal neurones in vitro

The sour side of vitamin C might mediate neuroprotective, anticonvulsive and antidepressant-like effects

The vagus nerve role in antidepressants action: efferent vagal pathways participate in peripheral anti-inflammatory effect of fluoxetine

The authors declare no conflicts of interest.